Immunomedics, Inc. Awarded Additional U.S. Patent for Anti-CD20 Treatment of Autoimmune Diseases

MORRIS PLAINS, N.J., Nov. 15, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the issuance of U.S. Patent 8,057,793 with additional claims for the patent family "Anti-CD20 antibodies and fusion proteins thereof and methods of use."